Compare AbbVie Inc (ABBV) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Texas Instruments Incorporated — how do they compare? AbbVie Inc trades at $253.8 (market cap $449.91B), while Texas Instruments Incorporated trades at $303.76 (market cap $266.93B). The key difference: AbbVie Inc is the larger of the two by market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | TXN | |
|---|---|---|
Market Cap | $449.91B | $266.93B |
Sector | Health | Technology |
52-Week High | $261.07 | $332.35 |
52-Week Low | $184.85 | $153.33 |
Enterprise Value | $513.38B | $275.88B |
Dividend Yield | 2.72% | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Texas Instruments (TXN) trades at $303.50, up 3.56% over 24 hours, with a bullish technical signal and strong profitability metrics including a 29.11% net income margin. Recent Q1 2026 earnings beat expectations, and the company announced a CFO transition with Julie Knecht set to succeed Rafael Lizardi in August 2026. Cash flow trends show improving operational performance, with 2025 operating cash flow at $7.15 billion.
The outlook remains positive with analyst consensus pointing to a $310.95 price target and 47.69% buy ratings. Key risks include elevated valuation ratios like a P/E of 51.88 and rising debt-to-asset ratio, now at 40.61% for 2025. Growth is supported by AI-driven demand in data centers, but investors should monitor execution on sequential revenue guidance and competitive pressures in the semiconductor space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
